Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EBIT (2016 - 2025)

Historic EBIT for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.4 million.

  • Lipocine's EBIT fell 2777.32% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.3 million, marking a year-over-year decrease of 1919.65%. This contributed to the annual value of -$1.2 million for FY2024, which is 9355.84% up from last year.
  • Lipocine's EBIT amounted to -$3.4 million in Q3 2025, which was down 2777.32% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Lipocine's EBIT ranged from a high of $12.8 million in Q4 2021 and a low of -$7.0 million during Q3 2023
  • Its 5-year average for EBIT is -$1.9 million, with a median of -$3.0 million in 2021.
  • Per our database at Business Quant, Lipocine's EBIT soared by 36623.94% in 2021 and then crashed by 16486.16% in 2025.
  • Quarter analysis of 5 years shows Lipocine's EBIT stood at $12.8 million in 2021, then plummeted by 120.03% to -$2.6 million in 2022, then decreased by 1.27% to -$2.6 million in 2023, then soared by 159.59% to $1.5 million in 2024, then plummeted by 317.48% to -$3.4 million in 2025.
  • Its last three reported values are -$3.4 million in Q3 2025, -$2.4 million for Q2 2025, and -$2.1 million during Q1 2025.